Eugenio Morelli
YOU?
Author Swipe
View article: Bedaquiline Amplifies Proteasome Inhibitor Efficacy and Overcomes Resistance in Multiple Myeloma
Bedaquiline Amplifies Proteasome Inhibitor Efficacy and Overcomes Resistance in Multiple Myeloma Open
Proteasome inhibitors (PIs) are cornerstone therapies for multiple myeloma (MM), yet resistance remains a major barrier to durable responses. To identify druggable vulnerabilities that enhance PIs efficacy, we performed a small-molecule ch…
View article: CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs Open
Long noncoding RNAs (lncRNAs) are a significant yet largely uncharted component of the cancer transcriptome, with their isoform-specific functions remaining poorly understood. In this study, we employed RNA-targeting CRISPR-Cas13d to uncov…
View article: Supplementary Figure S1 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S1 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S1. Expression profiling and correlation analysis of MYC and ACC1 in patients with newly diagnosed multiple myeloma (NDMM).
View article: Supplementary Figure S5 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S5 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S5. Gene set enrichment analysis in MM cells following ND-646 treatment, and evaluation of cell growth under combined treatment with ND-646 and simvastatin.
View article: Data from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Data from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Purpose:In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step in de novo lip…
View article: Supplementary Figure S2 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S2 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S2. Quantitative analysis of ACACA expression in multiple myeloma (MM) cell lines.
View article: Supplementary Figure S4 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S4 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S4. Impact of pharmacological inhibition (ND-630 and ND-646) and ACC1 knockdown on MM cell viability, proliferation, and de novo lipogenesis (DNL) rates in MYC overexpressed MM cells.
View article: Supplementary Figure S3 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Supplementary Figure S3 from Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Supplementary Figure S3. Representative western blot analysis showing protein levels of ACC1, phosphorylated ACC (pACC), and MYC in MM cells.
View article: Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma
Targeting Acetyl-CoA Carboxylase Suppresses <i>De Novo</i> Lipogenesis and Tumor Cell Growth in Multiple Myeloma Open
Purpose: In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step in de novo li…
View article: A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma
A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma Open
c-MYC (MYC) is an important oncogene in multiple myeloma (MM), driving MM cell proliferation, metabolism, and survival. However, MYC has been challenging to therapeutically target because of its protein structure lacking well-defined bindi…
View article: <i>Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.</i>
<i>Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.</i> Open
The genomic landscape of WM is characterized by mutations in MYD88 (MYD88MUT) and CXCR4 in 95-97% and 30-40% of patients, respectively. Transgenic mouse studies suggest that MYD88MUT alone is insufficient for lymphomagenesis and that addit…
View article: Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
DifferentialExpression_RNAseq
View article: Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Correlations of dBRD9-A susceptibility
View article: Supplementary Figure S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Clinical impact and biological significance of BRD9 in multiple myeloma (MM) in vitro and in vivo.
View article: Supplementary Figure S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
BRD9 depletion downregulates expression of ribosome biogenesis genes.
View article: Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
GSEA_RNAseq (GOBP)
View article: Supplemental Table S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplemental Table S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Univariate and multivariate analysis of BRD9 expression
View article: Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Supplementary Materials
View article: Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
BRD9 occupies promoter regions of target gene.
View article: Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
DifferentialExpression_RNAseq
View article: Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Supplementary Materials
View article: Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
BRD9 occupies promoter regions of target gene.
View article: Supplementary Figure S5 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S5 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
BRD9 co-localized with BRD4 and MYC in ribosome biogenesis gene transcription start sites (TSS).
View article: Supplementary Figure S5 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S5 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
BRD9 co-localized with BRD4 and MYC in ribosome biogenesis gene transcription start sites (TSS).
View article: Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Correlations of dBRD9-A susceptibility
View article: Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
GSEA_RNAseq (GOBP)
View article: Supplementary Figure S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
Ribosome biogenesis and translation signatures are upregulated in BRD9-depletion-sensitive MM cell lines.
View article: Supplementary Figure S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Supplementary Figure S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma Open
BRD9 depletion downregulates expression of ribosome biogenesis genes.